BMO Capital Markets Lowers BioNTech (NASDAQ:BNTX) Price Target to $128.00

BioNTech (NASDAQ:BNTX) had its price objective lowered by equities researchers at BMO Capital Markets from $143.00 to $128.00 in a research report issued to clients and investors on Wednesday, MarketBeat Ratings reports. The brokerage presently has an “outperform” rating on the stock. BMO Capital Markets’ price objective would suggest a potential upside of 42.06% from the stock’s previous close.

A number of other brokerages have also recently issued reports on BNTX. Berenberg Bank reiterated a “buy” rating on shares of BioNTech in a research note on Friday, January 23rd. Jefferies Financial Group lowered their target price on shares of BioNTech from $151.00 to $138.00 and set a “buy” rating on the stock in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $140.00 price target on shares of BioNTech in a research report on Thursday, December 11th. Bank of America reiterated a “buy” rating and issued a $128.00 price target on shares of BioNTech in a research note on Tuesday. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of BioNTech in a research report on Wednesday. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $133.73.

BioNTech Stock Performance

Shares of NASDAQ BNTX opened at $90.10 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.54. The stock has a 50 day moving average price of $106.54 and a 200 day moving average price of $102.66. The stock has a market capitalization of $20.29 billion, a PE ratio of -17.19 and a beta of 1.51. BioNTech has a 52 week low of $79.52 and a 52 week high of $124.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Larson Financial Group LLC raised its holdings in BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares during the period. EFG International AG bought a new stake in shares of BioNTech during the fourth quarter worth approximately $29,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after acquiring an additional 260 shares during the period. Financial Consulate Inc. acquired a new position in shares of BioNTech in the third quarter valued at approximately $36,000. Finally, Huntington National Bank increased its stake in shares of BioNTech by 1,266.7% during the third quarter. Huntington National Bank now owns 410 shares of the company’s stock worth $40,000 after purchasing an additional 380 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

Key Stories Impacting BioNTech

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Canaccord reiterated a “buy” rating and set a high $171 price target, signaling strong upside relative to the current level and supporting bullish investor thesis on long‑term mRNA opportunity. Canaccord reaffirms buy, $171 PT
• Positive Sentiment: Goldman Sachs reaffirmed its “buy” rating, providing another institutional vote of confidence that may stabilize sentiment among growth‑oriented holders. Goldman Sachs reaffirms buy
• Positive Sentiment: BioNTech and its co‑founders announced plans to pursue next‑generation mRNA innovations — a strategic signal that the company is investing in future product pipelines beyond COVID vaccines. Co‑founders pursue next‑gen mRNA
• Neutral Sentiment: Independent write‑ups are debating whether recent weakness makes BNTX a value play; the analysis highlights multi‑period share declines but leaves valuation conclusions to readers. Yahoo analysis on BNTX valuation
• Neutral Sentiment: Data feeds flagged a “large increase” in short interest, but the published figures are inconsistent (zeros/NaN and 0.0 days to cover), suggesting a likely reporting glitch rather than actionable short‑squeeze pressure.
• Neutral Sentiment: BMO trimmed its price target (to $128) but kept an “outperform” stance — a modest downgrade in optimism rather than a rout. BMO lowers PT to $128
• Negative Sentiment: Several outlets reported a steep share drop after an earnings miss and leadership changes (founder departures); that combination typically triggers near‑term selling and raises execution risk. Earnings miss & founder exodus — Blockonomi Earnings miss & leadership change — Tokenist
• Negative Sentiment: Multiple sell‑side revisions trimmed expectations: Citigroup lowered its PT to $130 (still a “buy”), TD Cowen cut to $94 and moved to “hold”, and Jefferies published more cautious forecasts — collectively cooling near‑term analyst enthusiasm. Citigroup cuts PT to $130 TD Cowen cuts to $94 Jefferies lowers expectations

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.